Chen Ching Wei Russell, Makkiya Mohammed, Aronow Wilbert, Spevack Daniel M
Division of Cardiology, Department of Medicine, Montefiore Medical Centre, Albert Einstein College of Medicine, Bronx, New York, USA.
Division of Cardiology, Department of Medicine, Westchester Medical Centre, New York Medical College, Valhalla, New York, USA.
Arch Med Sci. 2019 Dec 31;16(1):66-70. doi: 10.5114/aoms.2020.91287. eCollection 2020.
Several works have suggested heightened risk for cardiac events in cocaine users following percutaneous coronary intervention (PCI). Such studies have generally been performed in small, poorly defined samples and have not utilised optimal control groups. We aimed to define the short-term risk for death or recurrent myocardial infarction (MI) when PCI was performed for myocardial infarction in subjects presenting with urine toxicology positive for cocaine in relation to subjects testing negative for cocaine use.
Our institutional electronic health record (EHR) was queried for all subjects with urine toxicology performed for cocaine exposure within 5 days before or after having elevated troponin-T assay between 1/1/08 and 12/31/13. Query results were cross-referenced with our institutional cardiology database to identify the sample who had PCI on the same admission as the cocaine test. Subsequent readmission for MI was assessed from the EHR, and deaths were identified from the National Death Index.
PCI had been performed in 380 subjects who tested negative for cocaine and 44 subjects who tested positive. In the cocaine-positive group, incidences of death or MI at 30 days and 1 year were 18% and 23%, respectively. Those who tested positive for cocaine had increased odds (odds ratio (OR) = 2.3, 95% confidence interval (CI): 1.0-5.1, = 0.04) for death or MI at 30 days post PCI, after adjustment for age, sex, prior MI, and comorbidity index. Although the odds for events 1-year post PCI were not increased (OR = 2.0, 95% CI: 0.9-4.3), the -value approached significance in this small sample ( = 0.09).
This retrospective study suggests that PCI performed in cocaine-associated myocardial infarction comes with a high 30-day and one-year risk. Further prospective studies are needed to better define this risk and to lend insight into better management strategies.
多项研究表明,可卡因使用者在接受经皮冠状动脉介入治疗(PCI)后发生心脏事件的风险增加。此类研究通常在样本量小、定义不明确的情况下进行,且未使用最佳对照组。我们旨在确定在因心肌梗死接受PCI治疗的患者中,尿液毒理学检测可卡因呈阳性者与可卡因使用检测呈阴性者相比,死亡或复发性心肌梗死(MI)的短期风险。
查询我们机构的电子健康记录(EHR),以获取在2008年1月1日至2013年12月31日期间肌钙蛋白-T检测升高前后5天内进行过可卡因暴露尿液毒理学检测的所有受试者。查询结果与我们机构的心脏病数据库进行交叉核对,以确定在与可卡因检测同一天入院时接受PCI的样本。通过EHR评估随后因MI再次入院的情况,并从国家死亡指数中确定死亡病例。
380名可卡因检测呈阴性的受试者和44名检测呈阳性的受试者接受了PCI治疗。在可卡因阳性组中,30天和1年时死亡或MI的发生率分别为18%和23%。在调整年龄、性别、既往MI和合并症指数后,可卡因检测呈阳性者在PCI术后30天发生死亡或MI的几率增加(优势比(OR)=2.3,95%置信区间(CI):1.0 - 5.1,P = 0.04)。尽管PCI术后1年事件发生的几率没有增加(OR = 2.0,95%CI:0.9 - 4.3),但在这个小样本中P值接近显著性水平(P = 0.09)。
这项回顾性研究表明,在与可卡因相关的心肌梗死中进行PCI治疗,30天和1年的风险都很高。需要进一步的前瞻性研究来更好地确定这种风险,并深入了解更好的管理策略。